Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Lung Small Cell Carcinoma, P Subtype: early-phase trial registry

1 of 1 indexed Lung Small Cell Carcinoma, P Subtype trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Lung Small Cell Carcinoma, P Subtype: 1 US clinical trial tracked, 1 recruiting.

Lung Small Cell Carcinoma, P Subtype is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is SWOG Cancer Research Network, running 1 of these trials.

Enrollment posture brief

Registry condition lung-small-cell-carcinoma-p-subtype

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Lung Small Cell Carcinom (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Lung Small Cell Carcinoma, P Subtype

Lung Small Cell Carcinoma, P Subtype lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Small Cell Carcinoma, P Subtype on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Small Cell Carcinoma, P Subtype is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Lung Small Cell Carcinoma, P Subtype records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ceralasertib Drug
1 trials
Etoposide Drug
1 trials
Durvalumab Biological
1 trials
Computed Tomography Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Lung Small Cell Carcinoma, P Subtype trials. A trial with sites in several states counts in each.

Illinois 1 trials
Idaho 1 trials
Iowa 1 trials
Delaware 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Small Cell Carcinoma, P Subtype page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Lung Small Cell Carcinoma, P Subtype trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • SWOG Cancer Research Network sponsors the most Lung Small Cell Carcinoma, P Subtype trials on record, review their full trial history before evaluating a specific study. See SWOG Cancer Research Network's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Small Cell Carcinoma, P Subtype condition card totals 1 registered trials; most-linked intervention Ceralasertib; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.